Pharmaceuticals North America

North America Pneumococcal Vaccines Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

North America Pneumococcal Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

North America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.37 Bn Placeholder estimate
Estimate 2025 $5.62 Bn 55.6% of the global market
Projected 2034 $8.50 Bn 51.2% Adds $2.88 Bn over 9 forecast years
CAGR 2025–2034 4.7% Faster than 21% of 180 Pharmaceuticals markets here
Key players 5
  • North America is 55.61% of the global market.
  • Among regions, the largest is North America (this report) at $5.62 Bn.
  • Fastest growing: Latin America at 7.2% a year.
  • North America ranks 1st of 6 by size among regions.

Market size projection

North America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.88 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Pneumococcal Vaccines Market market size by year, North America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.37 Bn — —
2025 (base) $5.62 Bn +$252.4 Mn —
2026 (forecast) $5.89 Bn +$264.3 Mn +4.7%
2027 (forecast) $6.16 Bn +$276.7 Mn +9.6%
2028 (forecast) $6.45 Bn +$289.7 Mn +14.8%
2029 (forecast) $6.76 Bn +$303.3 Mn +20.2%
2030 (forecast) $7.08 Bn +$317.6 Mn +25.8%
2031 (forecast) $7.41 Bn +$332.5 Mn +31.7%
2032 (forecast) $7.76 Bn +$348.2 Mn +37.9%
2033 (forecast) $8.12 Bn +$364.5 Mn +44.4%
2034 (forecast) $8.50 Bn +$381.6 Mn +51.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

North America Pneumococcal Vaccines Market Analysis at a glance
Market size, 2025$5.62 Bn placeholder estimate
Forecast, 2034$8.50 Bn placeholder estimate
Growth (CAGR), 2025–20344.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, age and end user (see all)
Key playersPfizer Inc., Merck & Co., Inc., GSK PLC, Serum Institute of India, Vaxcyte (see all)
Active clinical trials31 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The North America Pneumococcal Vaccines Market Analysis Executive Summary

Pneumococcal vaccines protect against pneumonia, meningitis and blood infections caused by pneumococcus bacteria.

Key segments of the pneumococcal Vaccines market include type (Conjugate Vaccines and Polysaccharide Vaccines) and age (Infants, Older Adults and At-Risk Adults).

Bar chart: North America Pneumococcal Vaccines market size, 2024–2034, placeholder estimates. $5.37 Bn in 2024, $5.62 Bn in 2025 and $8.50 Bn in 2034, 4.7% CAGR.
North America Pneumococcal Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

North America Pneumococcal Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the pneumococcal Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the pneumococcal Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the pneumococcal Vaccines market.

Competitive Landscape for Pneumococcal Vaccines Market in North America

The pneumococcal Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pneumococcal Vaccines Market in North America

Pneumococcal Vaccines in North America: rules, payment and research

In the countries we cover here, medicines are approved by Health Canada (Canada)⁠[1] and FDA (US)⁠[2]. How care is paid for in these countries: provincial health insurance (Canada)⁠[3] and Medicare and Medicaid (US)⁠[4]. ClinicalTrials.gov lists 31 studies on Pneumococcal Vaccines that are recruiting, active or about to start in North America.⁠[5]

[1] Health Canada. Checked 14 Nov 2026.

[2] US Food and Drug Administration. Checked 14 Nov 2026.

[3] Health Canada. Checked 14 Nov 2026.

[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[5] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pneumococcal Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pneumococcal Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pneumococcal Vaccines in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pneumococcal Vaccines market in North America?
Placeholder estimate: about $5.62 Bn in 2025, rising to about $8.50 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pneumococcal Vaccines market in North America growing?
Placeholder estimate: about 4.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pneumococcal Vaccines market report cover?
The report splits the market by type (Conjugate Vaccines, Polysaccharide Vaccines), age (Infants, Older Adults, At-Risk Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Pneumococcal Vaccines market?
Key players include Pfizer Inc., Merck & Co., Inc., GSK PLC, Serum Institute of India and Vaxcyte.
What is driving the Pneumococcal Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the pneumococcal Vaccines market.
How many clinical trials on Pneumococcal Vaccines are running in North America?
31 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on Pneumococcal Vaccines?
PubMed lists 657 papers on Pneumococcal Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in North America

See all

Related on vaccines and respiratory

See the topic